In This Article:
The market is up 2.6% in the last 7 days, with all sectors gaining ground. Over the past 12 months, the market is up 44%, and earnings are forecast to grow by 17% annually. In this thriving environment, identifying stocks with strong financial foundations can be crucial for long-term success.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Yuken India | 27.96% | 12.35% | -44.41% | ★★★★★★ |
| Kokuyo Camlin | 27.11% | 23.20% | 75.70% | ★★★★★★ |
| Force Motors | 23.24% | 21.52% | 44.24% | ★★★★★☆ |
| Indo Tech Transformers | 2.30% | 22.04% | 60.31% | ★★★★★☆ |
| Spright Agro | 0.58% | 83.13% | 86.22% | ★★★★★☆ |
| Avantel | 10.67% | 34.84% | 36.61% | ★★★★★☆ |
| Kalyani Investment | NA | 21.42% | 6.35% | ★★★★★☆ |
| Magadh Sugar & Energy | 85.44% | 6.65% | 13.60% | ★★★★☆☆ |
| Sky Gold | 127.01% | 22.02% | 48.03% | ★★★★☆☆ |
| Innovana Thinklabs | 13.59% | 12.51% | 20.01% | ★★★★☆☆ |
Here's a peek at a few of the choices from the screener.
IIFL Securities
Simply Wall St Value Rating: ★★★★☆☆
Overview: IIFL Securities Limited offers a range of capital market services in India's primary and secondary markets with a market cap of ₹68.43 billion.
Operations: IIFL Securities generates revenue primarily from capital market activities (₹20.25 billion) and also earns significant income from insurance broking and ancillary services (₹2.77 billion).
IIFL Securities, a notable player in India's financial sector, has shown impressive earnings growth of 120.4% over the past year, outpacing the Capital Markets industry's 64%. The company's price-to-earnings ratio stands at a favorable 12.4x compared to the Indian market's 32.9x. Over five years, its debt to equity ratio improved from 117.6% to 67.2%, reflecting prudent financial management. Recent regulatory issues include a INR300K penalty by SEBI for incorrect client data entries but seem manageable given their overall performance trajectory and high-quality earnings.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ₹99.76 billion.
Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceuticals segment, which reported ₹22.68 billion. The company focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally.